Search results
HI-Bio Announces Positive Results from Phase 2 Study of Felzartamab for Late Antibody-Mediated ...
WWTI Watertown· 2 days ago82% (n=9/11) of patients on felzartamab experienced resolution of antibody-mediated rejection per Banff criteria on biopsy at 24 weeks versus 20% (n=2/10) who received placebo ...
Alien organs give hope of longer life
China Daily· 1 hour agoAlthough a living person can donate part of his or her liver without sacrificing his or her life, the operation in Anhui province is still a significant development because compatible liver ...
Hansa Biopharma to present data at 2024 American Transplant Congress annual meeting
WKRN Nashville· 6 days agoImlifidase has conditional marketing approval in Europe under the trade name IDEFIRIX® for the desensitization treatment of highly sensitized adult kidney transplant ...
Liver transplant from pig to human success in Anhui
China Daily· 12 hours agoRecently, a hospital in East China's Anhui province successfully transplanted a liver from a genetically modified pig into a human patient. The First Affiliated Hospital of ...
Nearly 20% of donated organs go unused — here’s how we can fix it and honor donors
Healthcare Dive· 4 days agoWhen we register as organ donors, we expect that our gifts will eventually go on to save lives. Last year alone, more than 10,000 organs recovered from generous donors — over 8,500 of which ...
Studies reveal cell-by-cell changes caused when pig hearts and kidneys are transplanted into humans
Medical Xpress· 5 days agoLed by researchers at NYU Grossman School of Medicine and the Broad Institute of MIT and Harvard,...
Biogen to acquire privately held Human Immunology Biosciences for $1.15 billion upfront
Market Watch· 5 days agoThe drug has received Breakthrough Therapy Designation and Orphan Drug Designation from the U.S....
Biogen enters deal to acquire HI-Bio for $1.8bn
Pharmaceutical Technology via Yahoo Finance· 4 days agoThe product also obtained ODD for antibody-mediated rejection in kidney transplant recipients. Beyond felzartamab, HI-Bio's pipeline ...
Biogen buys California biotech for $1.15 billion - The Boston Globe
The Boston Globe· 5 days agoBiogen said Wednesday it will acquire a California biotech that specializes in diseases of the...
Biogen (BIIB) to Buy HI-Bio to Expand Rare Disease Pipeline
Zacks via Yahoo Finance· 4 days agoAlso, phase II studies are completed in two other kidney diseases — primary membranous nephropathy...
